Pharmacology in rehabilitation: Nonsteroidal anti-inflammatory agents

Journal of Orthopaedic and Sports Physical Therapy

Volumn 35, Issue 6, 2005, Pages 356-367

  Biederman, Ross E ^a,b  

^a AMERICAN BOARD OF PODIATRIC SURGERY   (United States)

^b AZUSA PACIFIC UNIVERSITY   (United States)

Author keywords

Aspirin; COX 2 inhibitors; Ibuprofen; NSAID; Pharmacokinetics

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DIFLUNISAL; ETODOLAC; FENOPROFEN CALCIUM; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; MECLOFENAMATE SODIUM; NAPROXEN; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PIROXICAM; ROFECOXIB; SALSALATE; SULINDAC; TOLMETIN; VALDECOXIB;

ACUTE KIDNEY FAILURE; ALLERGIC REACTION; ANALGESIA; ANEMIA; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ANTIPYRETIC ACTIVITY; APHTHOUS ULCER; BLEEDING; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CONFUSION; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DISEASE ASSOCIATION; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DUODENUM ULCER; DYSPEPSIA; EDEMA; FLUID RETENTION; FRACTURE HEALING; HEARTBURN; HIGH RISK POPULATION; HUMAN; HYPERKALEMIA; KIDNEY PAPILLA NECROSIS; LIVER TOXICITY; MASS SCREENING; NAUSEA; NEPHRITIS; NEPHROTOXICITY; PHARMACOKINETICS; PHARMACOLOGY; PHYSIOTHERAPY; PRESCRIPTION; REHABILITATION; REVIEW; RISK BENEFIT ANALYSIS; SEDATION; SIDE EFFECT; SODIUM RETENTION; SOFT TISSUE; STATISTICAL SIGNIFICANCE; STOMACH DISEASE; STOMACH ULCER; STUPOR; TINNITUS; TREATMENT OUTCOME; TREATMENT PLANNING; WOUND HEALING IMPAIRMENT;

EID: 20044389684     PISSN: 01906011     EISSN: None     Source Type: Journal    
DOI: 10.2519/jospt.2005.35.6.356     Document Type: Review

References (49)

1. Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003;289:2819-2826.
2. Almekinders LC, Gilbert JA. Healing of experimental muscle strains and the effects of nonsteroidal antiinflammatory medication. Am J Sports Med. 1986;14:303-308.
3. American Physical Therapy Association. Guide to Physical Therapist Practice. Second Edition. American Physical Therapy Association. Phys Ther. 2001;81:9-746.
4. Arthritis Pain Society. APS Guideline for the Management of Pain in Osteoarthritis, Rheumatoid Arthritis and Juvenile Chronic Arthritis. Available at: http://www.ampainsoc.org/whatsnew/031502.htm. Accessed December 1, 2002.
5. Battie MC, Gherkin DC, Dunn R, Ciol MA, Wheeler KJ. Managing low back pain: attitudes and treatment preferences of physical therapists. Phys Ther. 1994;74:219-226.
6. Boissonnault WG. Prevalence of comorbid conditions, surgeries, and medication use in a physical therapy outpatient population: a multicentered study. J Orthop Sports Phys Ther. 1999;29:506-519; discussion 520-505.
7. Boissonnault WG, Koopmeiners MB. Medical history profile: orthopaedic physical therapy outpatients. J Orthop Sports Phys Ther. 1994;20:2-10.
8. Boissonnault WG, Meek PD. Risk factors for anti-inflammatory-drug- or aspirin-induced gastrointestinal complications in individuals receiving outpatient physical therapy services. J Orthop Sports Phys Ther. 2002;32:510-517.
9. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343:1520-1528.
10. Brooks P, Emery P, Evans JF, et al. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2. Rheumatology (Oxford). 1999;38:779-788.
11. Campo A, Thurlow W, Fored CM, Nyrén O. Acetaminophen, aspirin, and renal failure [letter]. N Engl J Med. 2002;346:1588-1589.
12. Carlstedt CA, Madsen K, Wredmark T. The influence of indomethacin on tendon healing. A biomechanical and biochemical study. Arch Orthop Trauma Surg. 1986;105:332-336.
13. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345:1809-1817.
14. Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002;296:539-541.
15. Ciccone CD. Pharmacology in Rehabilitation. 2nd ed. Philadelphia, PA: F.A. Davis; 1996.
16. Crofford LJ. Rational use of analgesic and anti-inflammatory drugs [editorial]. N Engl J Med 2000;345:1844-1845.
17. Daniel NG, Goulet J, Bergeron M, Paquin R, Landry PE. Antiplatelet drugs: is there a surgical risk? J Can Dent Assoc. 2002;68:683-687.
18. FDA Advisory Committee. Briefing Document NDA 21-042, s007. VIOXX Gastrointestinal Safety. Available at: www.fda.gov/ohrms/dockets/ac/01/briefing/ 3677b2_ 03_med.pdf. Accessed 2001.
19. Fenn CG. COX-2 inhibition and thrombotic tendency. Med J Aust. 2002;176:88-89; author reply 89.
20. Fitzmaurice DA, Blann AD, Lip GY. Bleeding risks of antithrombotic therapy. BMJ. 2002;325:828-831.
21. Flynn JE. Pharmacodynamic and pharmacokinetic principles of pharmacology and drug therapy. J Neurol Phys Ther. 2003;27:2793-2800.
22. Fored CM, Ejerblad E, Lindblad P, et al. Acetaminophen, aspirin, and chronic renal failure. N Engl J Med. 2001;345:1801-1808.
23. Giannoudis PV, MacDonald DA, Matthews SJ, Smith RM, Furlong AJ, De Boer P. Nonunion of the femoral diaphysis. The influence of reaming and non-steroidal anti-inflammatory drugs. J Bone Joint Surg Br. 2000;82:655-658.
24. Gille J, Bernotat J, Bohm S, Behrens P, Lohr JF. Spontaneous hemarthrosis of the knee associated with clopidogrel and aspirin treatment. Z Rheumatol. 2003;62:80-81.
25. Glassman SD, Rose SM, Dimar JR, Puno RM, Campbell MJ, Johnson JR. The effect of postoperative nonsteroidal anti-inflammatory drug administration on spinal fusion. Spine. 1998;23:834-838.
26. Gorelick PB, Richardson D, Kelly M, et al. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA. 2003;289:2947-2957.
27. Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289:1107-1116.
28. Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman C. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill; 1996.
29. Jones R. Efficacy and safety of COX 2 inhibitors. BMJ. 2002;325:607-608.
30. Kam PC, Power A. The new selective COX-II inhibitors. Pain Rev. 2000;1:22.
31. Kimmel SE. Penn Epidemiological Study Shows Difference in Cardiovascular Effects Between Vioxx and Celebrex. Available at: http://www.uphs.upenn.edu/ news/News_Releases/dec04/COX2Kimmel_print.htm. Accessed December 5, 2004.
32. Lahlik L. An Update on Nonsteroidal Anti-inflammatory Agents. Available at: http://daccx.bsd.uchicago.edu/ drug/Bulletins/n0596.html. Accessed December 5, 1996.
33. Lichtenstein DR, Wolfe MM. COX-2-Selective NSAIDs: new and improved? JAMA. 2000;284:1297-1299.
34. Lonner JH. A 57-year-old man with osteoarthritis of the knee. JAMA. 2003;289:1016-1025.
35. Merck Research Laboratories. Remarks of Peter S. Kim, President Merck Research Laboratories. Available at: http://www.merck.com/newsroom/ vioxxwithdrawel/pdf/10_13_2004psk.pdf.Accessed November 11, 2004.
36. Mizuno H, Sakamoto C, Matsuda K, et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology. 1997;112:387-397.
37. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286:954-959.
38. Reynolds JF, Noakes TD, Schwellnus MP, Windt A, Bowerbank P. Non-steroidal anti-inflammatory drugs fail to enhance healing of acute hamstring injuries treated with physiotherapy. S Afr Med J. 1995;85:517-522.
39. Safavi KT, Hayward RA. Choosing between apples and apples: physicians' choices of prescription drugs that have similar side effects and efficacies. J Gen Intern Med. 1992;7:32-37.
40. Sano H, Hla T, Maier JA, et al. In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J Clin Invest. 1992;89:97-108.
41. Schmassmann A, Peskar BM, Stettler C, et al. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats. Br J Pharmacol. 1998;123:795-804.
42. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284:1247-1255.
43. Simon LS. Actions and toxicity of nonsteroidal anti-inflammatory drugs. Curr Opin Rheumatol. 1995;7:159-166.
44. Spiegel BM, Targownik L, Dulai GS, Gralnek IM. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann Intern Med. 2003;138:795-806.
45. Steering Committee of the Physicians' Health Study Group. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med. 1989;321:129-135.
46. Stucki G, Johannesson M, Liang MH. Is misoprostol cost-effective in the prevention of nonsteroidal anti-inflammatory drug-induced gastropathy in patients with chronic arthritis? A review of conflicting economic evaluations. Arch Intern Med. 1994;154:2020-2025.
47. Wallace JL, McKnight W, Reuter BK, Vergnolle N. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology. 2000;119:706-714.
48. Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med. 2000;160:2998-3003.
49. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999;340:1888-1899.